Are we closer to gene therapy for sickle cell disease being accessible?

Sickle cell disease, a debilitating inherited blood disorder affecting millions globally, faces a potential turning point with the advent of gene therapy. While this treatment offers a transformative cure by modifying a patient's own stem cells, its accessibility remains severely limited by a prohibitive cost of at least two million dollars per patient. Beyond financial barriers, the global burden is concentrated in sub-Saharan Africa, where inadequate healthcare infrastructure, lack of early diagnosis, and cultural stigma hinder effective management. Current efforts focus on developing more affordable, in vivo gene therapy and improving basic care through newborn screening and hydroxyurea. Despite these advancements, the vast disparity in survival rates between high-income countries and regions like Nigeria underscores that scientific breakthroughs have yet to translate into equitable public health solutions for the most vulnerable populations.